quinazolines has been researched along with Corneal Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, JS; Ahn, MJ; Chung, TY; Han, J; Jung, HA; Kang, WK; Lee, J; Lee, SH; Lim, DH; Nam, DH; Park, K; Shin, E; Sun, JM | 1 |
| Jiang, Q; Li, JJ; Li, XM; Lu, C; Tao, SY; Yan, B; Yao, J; Zhang, QY | 1 |
| Arriola-Villalobos, P; Benítez-Del-Castillo, JM; Benito-Pascual, B; Díaz-Valle, D | 1 |
| Chu, DS; Johnson, KS; Levin, F | 1 |
| Fine, HA; Smith, JA; Yeh, S | 1 |
| Ahn, J; Hyon, JY; Lee, JH; Wee, WR | 1 |
| Ashizawa, J; Deguchi, Y; Hashimoto, R; Hitani, K; Hori, Y; Maeno, T; Shiba, T; Ubuka, M | 1 |
7 other study(ies) available for quinazolines and Corneal Diseases
| Article | Year |
|---|---|
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity | 2020 |
SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.
Topics: Animals; Burns, Chemical; Cell Movement; Cell Proliferation; Cornea; Corneal Diseases; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred ICR; Neovascularization, Physiologic; Ophthalmic Solutions; Quinazolines; Signal Transduction; Thiadiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Corneal Diseases; Female; Humans; Male; Microscopy, Confocal; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2018 |
Persistent corneal epithelial defect associated with erlotinib treatment.
Topics: Aged; Cataract Extraction; Corneal Diseases; Epithelium, Corneal; Erlotinib Hydrochloride; Female; Humans; Keratitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections; Staphylococcus epidermidis | 2009 |
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; Cellulase; Corneal Diseases; Corneal Opacity; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ointments; Piperidines; Quinazolines; Retrospective Studies; Sodium Chloride; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cornea; Corneal Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Microscopy, Acoustic; Piperidines; Quinazolines; Visual Acuity | 2011 |
[A case of a corneal disorder after lung cancer treatment with erlotinib].
Topics: Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |